Navigate to
-
FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...
-
Clinical Solutions VP (Remote) Looking for your next career move and want to help Prime Therapeutics (Prime) put more care in health care? Check out the Prime Careers Spotlight, a monthly roundup...
-
Oral selective estrogen receptor degraders Agent Status and key trial data What to watch Elacestrant (Orserdu) Approved in 2023 as the first oral SERD in ESR1-mutant metastatic breast cancer via...
-
Tab 1 BEHAVIORAL HEALTH CORNER WEIGHT MANAGEMENT CORNER Clinical News EDITOR-IN-CHIEF: Maryam Tabatabai, PharmD EXECUTIVE EDITOR: Anna Schreck Bird, PharmD DEPUTY EDITORS: Erik Hamel, PharmD;...
-
Drug name/Manufacturer/Dosage form retatrutide/Eli Lilly/SC Drug name/Manufacturer/Dosage form semaglutide (Wegovy)/Novo Nordisk/SC tirzepatide (Zepbound)/Eli Lilly/SC T2DM Access the complete...
-
Greg Myers, vice president of AI strategy at Prime Therapeutics, shares how AI is creating value for healthcare payers — and what it takes to scale it responsibly
Prime Article: Stories -
The CDC is reporting influenza-like illness (ILI) for the week ending March 15, 2025 (week 11). Seasonal influenza activity remains increased across the U.S. but has decreased for five consecutive...
-
While AI has helped streamline many processes, its ultimate impact may be debatable at this point, and caution in certain areas is warranted, according to some industry experts
Prime Article: In the News